After AI Finds a Candidate, What Gets Paid For? ↗
A business comparison of who holds asset rights and bears development costs.
Frozen card revision. This is the recorded reading, not an automatically refreshed view. Current card ↗
Commercialization · TOPIC v1
What Does Chugai Still See in a Drug Roche Is Walking Away From?
Which patients and product proposition could make a discontinued program viable?
Read article → What Does Chugai Still See in a Drug Roche Is Walking Away From?
2026-09-29 15:11:40.000 UTC · Last recorded update
CURRENT READING
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
Recorded editorial state, not a maturity score
- Reports and agreements reviewedRecorded
- Further validationUnverified
- Adoption and benefitUnverified
New question opened · v1
Recorded a new question and follow-up checks from the approved manuscript.
Permanent link to this revision ↗01 / WHAT WE TRACK
Which patients and product proposition could make a discontinued program viable?
02 / EVIDENCE & TECHNOLOGY
Anti-myostatin antibodies / SMA / subcutaneous administration
03 / EDITORIAL READING
The decision may preserve an option by redesigning the product proposition and financing arrangement.
04 / WHAT REMAINS UNKNOWN
Restart preparations do not vindicate efficacy. Injection convenience and a competitor’s success do not establish GYM329 benefit.
05 / NEXT CHECK
Patient selection, functional endpoints, long-term evidence and licensing terms.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDA benefit in a specific SMA population, combined with a different administration route, could support a different investment decision.
What would change our view: Reconsider if a narrower population still shows no meaningful functional benefit, or viable partnership terms cannot be found.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsINSTITUTION / INFRASTRUCTUREChugai Pharmaceutical ↗
Mentioned in this issue
INSTITUTION / INFRASTRUCTURERoche ↗
Mentioned in this issue
INSTITUTION / INFRASTRUCTUREScholar Rock ↗
Mentioned in this issue
INSTITUTION / INFRASTRUCTUREGYM329 ↗
Mentioned in this issue
Related questions, optional follows
Map ↗Latest card updates
Latest 5 · editorial record dates- v1 · 2026-09-29 15:11:40.000 UTCNew question opened
Recorded a new question and follow-up checks from the approved manuscript.
Reading at the time: As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Background readings
Source dates and verification scope
9月28日の発表 ↗
www.chugai-pharm.co.jp · recorded 2026-09-29 · linked-primary-source
Rocheの学会報告 ↗
medically.roche.com · recorded 2026-09-29 · linked-primary-source
SAPPHIRE原著 ↗
www.sciencedirect.com · recorded 2026-09-29 · linked-primary-source
競合試験の説明 ↗
scholarrock.gcs-web.com · recorded 2026-09-29 · linked-primary-source